Skip to main content

Venture Capital Firm  I  Home


A Venture Capital Firm for Visionary Innovators.

Advent Life Sciences is one of the leading trans-Atlantic venture investors focused on building innovative Life Sciences businesses in the UK, Europe and the USA.

We are a highly experienced team with a long-standing track record of entrepreneurial and investment success. We do this by turning break-through science into approved medicines or medical products.

We start and invest in early and mid-stage companies with a first-in-class or best-in-class approach.
Our investments are focused on new drug discovery across all modalities, med tech, enabling technologies and vaccines.

As entrepreneurs and experienced, pragmatic investors, we bring the intellectual capital of our well-connected team to support each investment.

We take a hands-on approach and work in close alignment and partnership with our management teams to realise their vision with the goal of achieving superior financial returns by bringing innovation to patients.


We are backing exceptional innovation early.

Since the year 2006, Advent-backed companies have brought fourteen innovative medicines and products to approval with our initial investment often being as early as Seed stage or Series A.

As the mid- and late-stage clinical pipelines of our portfolio companies continue to grow, this number looks set to increase each year.


Latest Press Releases

13 January 2023 in Pheno Therapeutics, Press Release, Private Companies

Pheno Therapeutics Announces Worldwide License From UCB to a Novel Program for Neurodegenerative Disease

Press Release.   Preclinical program with potential for disease modifying therapeutic Edinburgh, UK January 11 2023 – Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of…
Read More
19 December 2022 in F2G, Press Release, Private Companies

F2G Announces FDA Filing Acceptance of New Drug Application for Olorofim for the Treatment of Invasive Fungal Infections

Press Release.   Application submitted under priority review with PDUFA target action date set for June 17, 2023 NDA submission is based on positive data from ongoing Phase 2b open-label…
Read More
1 December 2022 in Aura Biosciences, Press Release, Publicly Listed

Aura Biosciences Announces Pricing of Public Offering of Common Stock

Press Release. BOSTON--(BUSINESS WIRE)-- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced…
Read More


Leading Venture Investors
Learn More


Innovative Life Sciences Companies
Learn More